ProCE Banner Activity

Expert-Informed Strategies for Diagnosing and Managing Tardive Dyskinesia

Clinical Thought

Advanced practice providers who care for patients treated with dopamine receptor blocking agents (eg, antipsychotics) should be vigilant for symptoms of tardive dyskinesia and aware of the impact this disorder can have on patients’ quality of life. Learn strategies with these answers to frequently asked questions regarding screening, monitoring, and treatment of tardive dyskinesia.

Released: July 25, 2024

Expiration: July 24, 2025

Share

Faculty

Jeremy A. Schreiber

Jeremy A. Schreiber, MSN, APRN, PMHNP-BC

Adjunct Faculty
Department of Health Sciences
West Liberty University
West Liberty, West Virginia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

Disclosure

Primary Author

Jeremy A. Schreiber, MSN, APRN, PMHNP-BC

Adjunct Faculty
Department of Health Sciences
West Liberty University
West Liberty, West Virginia

Jeremy A. Schreiber, MSN, APRN, PMHNP-BC: consultant/advisor/speaker:  AbbVie, Alkermes, Allergan, Axsome, Biogen, Bristol Myers Squibb, Intra-Cellular Therapies, Janssen, Karuna, Neurocrine Biosciences, Otsuka, Sage, Teva, Vanada.